Recovery & Repair · IGF-1 splice variant · Compounded 503A
PEG-MGF: pegylated mechano growth factor.
PEG-MGF is a pegylated form of mechano growth factor (MGF) — an alternative splice variant of IGF-1 produced locally in muscle in response to mechanical loading and damage. It activates satellite cells, the muscle stem-cell population responsible for repair and hypertrophy. The pegylation extends its very short native half-life into a clinically useful window.
What PEG-MGF is
MGF (mechano growth factor) is an alternative splice variant of insulin-like growth factor-1 (IGF-1Ec) produced by skeletal muscle in response to mechanical loading and damage. It is the local 'repair signal' that recruits muscle stem cells.
Native MGF has an extremely short half-life (minutes). PEG-MGF attaches a polyethylene glycol moiety to the molecule, extending half-life into hours-to-days and making clinical dosing feasible.
It is used in compounded practice as a recovery adjunct for adults with muscle-loss conditions, athletes (non-tested) working through structured rehabilitation, and longevity-focused patients addressing sarcopenia.
How it works
MGF binds a distinct receptor profile from systemic IGF-1, signaling preferentially to satellite cells (the muscle stem-cell population that sits adjacent to muscle fibers in a quiescent state).
Activation of satellite cells drives their proliferation, fusion with damaged muscle fibers, and incorporation of new myonuclei — the cellular basis of muscle repair and hypertrophy.
Mechanistically, MGF acts locally — in healthy biology it is produced by the damaged muscle itself and acts on adjacent stem cells. Exogenous PEG-MGF delivers this signal more broadly.
What patients use it for
Satellite-cell activation
The defining mechanism — recruits muscle stem cells, increasing the cellular substrate available for repair and growth.
Post-training recovery
May reduce time to recovery between heavy training sessions; particularly useful in concentrated training blocks or post-injury rehab.
Sarcopenia interest
Muscle-loss conditions (age-related sarcopenia, cachexia) involve impaired satellite-cell function — PEG-MGF is studied for this mechanism.
Complementary to GH-axis protocols
Works at a different level than systemic GH/IGF-1 — local muscle stem-cell signal rather than systemic anabolic drive.
Evidence summary
Yang SY, Goldspink G (FEBS Lett, 2002) — foundational paper characterizing MGF as a unique splice variant with distinct satellite-cell-activating activity.
Mills P et al. (Mol Ther, 2007) demonstrated MGF's role in muscle stem-cell activation and repair.
Philippou A, Barton ER (Trends Endocrinol Metab, 2014) reviewed MGF and other IGF-1 splice variants in muscle biology.
Direct large-scale human RCT data for PEG-MGF is limited; most evidence is preclinical and from related growth-factor literature.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Subcutaneous injection. Some protocols use local injection adjacent to a specific recovering muscle group (the 'site-specific' approach inherited from the local nature of native MGF signaling).
Often dosed post-training to amplify the satellite-cell response to the training stimulus.
Course-based use during heavy training blocks or rehabilitation periods is most common.
Safety and contraindications
Long-term human safety data is limited.
Theoretical concerns: any IGF-axis activator carries potential risk for tissues with growth-factor-sensitive pathology (active malignancy especially).
Contraindications: active cancer, pregnancy/lactation, pediatric use, known hypersensitivity.
Banned by WADA for competitive athletes (S2 growth factors / mimetics).
Not FDA-approved; compounded by licensed 503A pharmacies under physician prescription.
Who it's typically considered for
- Adults in structured rehabilitation from muscle injury or surgical recovery
- Athletes (non-tested) working through concentrated training blocks under physician supervision
- Patients with early sarcopenia pursuing muscle-protection protocols
- Patients combining with resistance training rather than substituting for it
Frequently asked questions
PEG-MGF vs IGF-1 LR3?
IGF-1 LR3 is a long-acting systemic IGF-1 analog — broad anabolic signal across all IGF-1R tissues. PEG-MGF is a splice variant targeting satellite cells specifically. Different signal, different application.
PEG-MGF vs BPC-157 or TB-500?
BPC-157 and TB-500 are general tissue-repair peptides (gut, tendon, ligament focus). PEG-MGF is muscle-stem-cell specific. They are complementary, not interchangeable.
Will PEG-MGF replace training?
No. Satellite-cell activation requires a stimulus to act on — without training, there is little muscle damage to repair and little hypertrophy signal to amplify.
Is PEG-MGF banned in sport?
Yes — WADA lists growth factors and growth-factor mimetics as prohibited (S2). Tested athletes should not use it.
Is PEG-MGF FDA-approved?
No. It is compounded by licensed 503A pharmacies under physician prescription for off-label use.
Can women use PEG-MGF?
Yes — particularly post-menopausal women addressing sarcopenia risk, under physician supervision. Muscle biology of satellite-cell activation is similar across sexes.
Sources
- Yang SY, Goldspink G. Different roles of the IGF-1Ec peptide (MGF) and mature IGF-1 in myoblast proliferation. FEBS Lett (2002). — pubmed.ncbi.nlm.nih.gov/12095641
- Philippou A, Barton ER. Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res (2014). — pubmed.ncbi.nlm.nih.gov/25117005
- Mills P et al. A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success. Mol Ther (2007). — pubmed.ncbi.nlm.nih.gov/17593928
Considering PEG-MGF?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.